Your browser doesn't support javascript.
loading
IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer.
Colomer, Carlota; Margalef, Pol; Villanueva, Alberto; Vert, Anna; Pecharroman, Irene; Solé, Laura; González-Farré, Mónica; Alonso, Josune; Montagut, Clara; Martinez-Iniesta, Maria; Bertran, Joan; Borràs, Eva; Iglesias, Mar; Sabidó, Eduard; Bigas, Anna; Boulton, Simon J; Espinosa, Lluís.
Afiliação
  • Colomer C; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Doctor Aiguader 88, Barcelona 08003, Spain.
  • Margalef P; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Doctor Aiguader 88, Barcelona 08003, Spain; DSB Repair Metabolism Laboratory, The Francis Crick Institute, London NW1 1AT, UK.
  • Villanueva A; Translational Research Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Institut Català d'Oncologia, Hospitalet, Barcelona 08907, Spain.
  • Vert A; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Doctor Aiguader 88, Barcelona 08003, Spain.
  • Pecharroman I; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Doctor Aiguader 88, Barcelona 08003, Spain.
  • Solé L; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Doctor Aiguader 88, Barcelona 08003, Spain.
  • González-Farré M; Department of Pathology, Institut Mar d'Investigacions Mèdiques, CIBERONC, Universitat Autònoma de Barcelona, Barcelona 08003, Spain.
  • Alonso J; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Doctor Aiguader 88, Barcelona 08003, Spain.
  • Montagut C; Department of Oncology, Institut Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra, CIBERONC, Barcelona 08003, Spain.
  • Martinez-Iniesta M; Translational Research Laboratory, Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Institut Català d'Oncologia, Hospitalet, Barcelona 08907, Spain.
  • Bertran J; Faculty of Science and Technology, Bioinformatics and Medical Statistics Group, University of Vic-Central University of Catalonia, Vic 08500, Spain.
  • Borràs E; Proteomics Unit, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona 08003, Spain; Proteomics Unit, Universitat Pompeu Fabra, Barcelona 08003, Spain.
  • Iglesias M; Department of Pathology, Institut Mar d'Investigacions Mèdiques, CIBERONC, Universitat Autònoma de Barcelona, Barcelona 08003, Spain.
  • Sabidó E; Proteomics Unit, Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST), Barcelona 08003, Spain; Proteomics Unit, Universitat Pompeu Fabra, Barcelona 08003, Spain.
  • Bigas A; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Doctor Aiguader 88, Barcelona 08003, Spain. Electronic address: abigas@imim.es.
  • Boulton SJ; DSB Repair Metabolism Laboratory, The Francis Crick Institute, London NW1 1AT, UK. Electronic address: simon.boulton@crick.ac.uk.
  • Espinosa L; Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Doctor Aiguader 88, Barcelona 08003, Spain. Electronic address: lespinosa@imim.es.
Mol Cell ; 75(4): 669-682.e5, 2019 08 22.
Article em En | MEDLINE | ID: mdl-31302002
ABSTRACT
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be defined. Here, we discover that IKKα(p45) is rapidly activated by DNA damage independent of ATM-ATR, but dependent on BRAF-TAK1-p38-MAPK, and is required for robust ATM activation and efficient DNA repair. Abolishing BRAF or IKKα activity attenuates ATM, Chk1, MDC1, Kap1, and 53BP1 phosphorylation, compromises 53BP1 and RIF1 co-recruitment to sites of DNA lesions, and inhibits 53BP1-dependent fusion of dysfunctional telomeres. Furthermore, IKKα or BRAF inhibition synergistically enhances the therapeutic potential of 5-FU and irinotecan to eradicate chemotherapy-resistant metastatic human tumors in vivo. Our results implicate BRAF and IKKα kinases in the DDR and reveal a combination strategy for cancer treatment.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dano ao DNA / Resistencia a Medicamentos Antineoplásicos / Sistema de Sinalização das MAP Quinases / Quinase I-kappa B / Fluoruracila / Irinotecano / Proteínas de Neoplasias / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Dano ao DNA / Resistencia a Medicamentos Antineoplásicos / Sistema de Sinalização das MAP Quinases / Quinase I-kappa B / Fluoruracila / Irinotecano / Proteínas de Neoplasias / Neoplasias Limite: Animals / Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article